DHR Stock Recent News

Danaher Corporation incorporates science and technology and has a market cap of $150B. The company has mixed financials, with its gross profit margin being its strongest and most consistent. DHR doesn't offer much in terms of dividend yield, but its above-average dividend growth could be attractive for dividend investors.

Danaher is well-positioned for revenue growth, driven by strong Biotechnology orders, Chinese stimulus in Life Sciences, and innovative products in Diagnostics despite near-term headwinds. Margins face short-term pressure from China's VBP initiative, but cost-cutting measures and operational efficiency should drive long-term margin expansion. The stock is undervalued compared to historical levels, trading at a discount to its average forward P/E over the last five years.

Highlighting eight companies with upcoming dividend increases, four exceeding 10%, and an average increase of 11.4%, median at 9%. My investment strategy focuses on buying, holding, and expanding stakes in companies with consistent dividend growth and benchmark-beating performance. The list is curated using data from the "U.S. Dividend Champions" spreadsheet and NASDAQ, ensuring a minimum of five years of dividend growth.

Danaher Corporation is trading near its 5-year low, presenting a potential buying opportunity for growth investors despite near-term headwinds. DHR's strong fundamentals include leadership in biotechnology, life sciences, and diagnostics, with robust profitability and free cash flow. Growth catalysts include advancements in bioprocessing, molecular diagnostics, and neurodegenerative disease detection, with expected EPS growth of 10%-13% annually over the next three years.

WASHINGTON , March 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2025 on Tuesday, April 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour.

Persistent softness in the Life Sciences segment weighs on DHR's performance. An increase in operating expenses is an added concern.

The new DxC 500i Analyzer Offers Flexibility and Scalability with Broad Chemistry and Immunoassay Assay Menu BREA, Calif. , March 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the new DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay analyzer, received 510(k) clearance from the U.S. Food and Drug Administration.

Danaher Corporation (NYSE:DHR ) TD Cowen 45th Annual Health Care Conference Call March 5, 2025 10:30 AM ET Company Participants Rainer Blair – President and Chief Executive Officer Conference Call Participants Dan Brennan – TD Cowen Dan Brennan Welcome to day-three of the TD Cowen Global Healthcare Conference. I'm Dan Brennan, I follow tools and diagnostics.

WASHINGTON , Feb. 25, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Wednesday, March 5, 2025 at 10:30 a.m.

DHR's measures to consistently reward shareholders through dividends and share buybacks hold promise.